4831-43-0

Usage

Uses

Used in Chemical Industry:
3,3-Dimethyl-2-pyrrolidinone is used as a solvent for its ability to dissolve a wide range of substances, facilitating various chemical reactions and processes.
Used in Polymer and Resin Production:
3,3-Dimethyl-2-pyrrolidinone is used as a solvent in the production of polymers and resins, contributing to the manufacturing process due to its solubility and stability properties.
Used in Petrochemical Processing:
3,3-Dimethyl-2-pyrrolidinone is used as a processing aid in the petrochemical industry, where its thermal and chemical stability are advantageous for certain refining processes.
Used in Pharmaceutical Manufacturing:
3,3-Dimethyl-2-pyrrolidinone is used as a solvent in the pharmaceutical industry, aiding in the formulation and synthesis of various drugs.
Used in Agrochemical Production:
3,3-Dimethyl-2-pyrrolidinone is used in the manufacturing of agrochemicals, where its properties help in the development of effective agricultural products.
Safety Considerations:
Due to its potential health risks when inhaled, ingested, or in contact with the skin and eyes, 3,3-Dimethyl-2-pyrrolidinone requires careful handling and protection measures to ensure the safety of those working with the chemical.

Upstream product

• 7646-66-4 N-benzoylaziridine 
• 97-62-1 Ethyl isobutyrate 
• 121103-60-4 3,3-dimethyl-5-thioxopyrrolidin-2-one 
• 14468-90-7 N-trimethylsilyl-pyrrolidin-2-one 
• 74-88-4 methyl iodide 
• 195447-78-0 3,3-dimethyl-2-oxo-1-pyrrolidinecarboxylic acid, 1,1-dimethylethyl ester, hydrochloride 
• 153039-16-8 tert-butyl 3,3-dimethyl-2-oxo-pyrrolidine-1-carboxylate 
• 924884-26-4 1-[(1,1-dimethylethyl)(dimethyl)silyl]-3,3-dimethyl-2-pyrrolidinone 
• 3437-29-4 3,3-dimethylpyrrolidine-2,5-dione 

Downstream Products

• 127103-83-7 3,3-dimethylpyrrolidine-2-thione 
• 153039-16-8 tert-butyl 3,3-dimethyl-2-oxo-pyrrolidine-1-carboxylate 
• 924884-28-6 benzyl 3,3-dimethyl-2-oxo-1-pyrrolidinecarboxylate 
• 1458027-25-2 2-(3,3-dimethyl-2-oxopyrrolidin-1-yl)-N-methyl-N,2-diphenylacetamide 
• 1458027-39-8 3-(3,3-dimethyl-2-oxopyrrolidin-1-yl)-1-methyl-3-phenylindolin-2-one 
• 742067-40-9 1-(4-hydroxy-phenyl)-3,3-dimethyl-pyrrolidin-2-one 
• 195447-24-6 N-(3,4-Dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-N-?((2-methoxyethoxy)methyl)-4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamid 

Relevant academic research and scientific papers

Effect of Differential Geminal Substitution of γAmino Acid Residues at the (i + 2) Position of αγTurn Segments on the Conformation of Template β-Hairpin Peptides

The effect of insertion of three geminally dimethyl substituted γamino acid residues [γ2,2 (4-amino-2,2-dimethylbutanoic acid), γ3,3 (4-amino-3,3-dimethylbutanoic acid), and γ4,4 (4-amino-4,4-dimethylbutanoic acid)] at the (i + 2) position of a two-residue αγC12 turn segment in a model octapeptide sequence Leu-Phe-Val-Aib-Xxx-Leu-Phe-Val (where Xxx = γamino acid residues) has been investigated in this study. Solution conformational studies (NMR, CD, and IR) and ab initio calculations indicated that γ3,3 and γ4,4 residues were well accommodated in the β-hairpin nucleating αγC12 turns, which gave rise to well-registered hairpins, in contrast to γ2,2, which was unable to form a tight C12 β-hairpin nucleating turn and promote a well-registered β-hairpin. Geminal disubstitution at the Cα carbon in γ2,2 led to unfavorable steric contacts, disabling its accommodation in the αγC12 hairpin nucleating turn unlike the γ3,3 and γ4,4 residues. Geminal substitutions at different carbons along the backbone constrained backbone torsion angles for the three γamino acid residues differently, generating diverse conformational preferences in them. Folded hairpins were energetically more stable (～8 to 9 kcal/mol) than the unfolded peptides. Conformational preference of the peptides was independent of the N-terminal protecting group. Such fundamental understanding will instrumentalize the future directed design of foldamers.

N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF

An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS

Compounds of formula I (formula I), wherein A is an optionally substituted five-membered unsaturated heterocyclic ring containing 1, 2 or 3 N, O or S ring heteroatom(s) exhibit alpha2C antagonistic activity and are thus useful for the treatment of diseases or conditions of the peripheric or central nervous system.

COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF

Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES

A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, formula (I): wherein: R1 is C3-8-cycloalkyl; X is O, NR7 or C3-6-heterocycloalkyl; R2 is aryl, heteroaryl, fused or unfused aryl-C3-6-heterocycloalkyl or fused or unfused heteroaryl-C3-6-heterocycIoalkyl, each of which is optionally substituted by one or more substitutents selected from aryl, heteroaryl, C1-6-alkyl, C3-7-cycloalkyl and a group A, wherein said C1-6-alkyl group is optionally substituted by one or more substituents selected from aryl, heteroaryl, R10 and a group A, said heteroaryl group is optionally substituted by one or more R10 groups; and wherein said C3-6-heterocycloalkyl group optionally contains one or more groups selected from oxygen, sulfur, nitrogen and CO; R3 is C1-6-alkyl optionally substituted by one or more substituents selected from aryl, heteroaryl, -NR4R5, -OR6, -NR7(CO)R6, -NR7(CO)NR4R5, -NR7SO2R6, -NR7COOR7, -CONR4R5, C3-6-heterocycloalkyl and formula (a, b, c): wherein R4-7 and A are as defined in the claims. Further aspects relate to the use of said compounds in the treatment of various therapeutic disorders, and more particularly as inhibitors of one or more kinases.

Benzyl 2-cyano-3,3-dimethyl-1-pyrrolidinecarboxylate, a versatile intermediate for the synthesis of 3,3-dimethylproline derivatives

(Chemical Equation Presented) The synthesis of racemic nitrile (±)-9 was accomplished in four steps and 58% overall yield from the known pyrrolidinone 5. Nitrile (±)-9 was resolved via preparative chiral HPLC to afford optically pure nitriles (+)-9 and (-

PEPTIDE DEFORMYLASE INHIBITORS

Novel PDF inhibitors and novel methods for their use are provided.

ENDOTHELIN ANTAGONISTS: N- 2'- (4,5-DIMETHYL-3-ISOXAZOLYL) AMINO]SULFONYL]-4-(2-OXAZOLYL) 1,1'-BIPHENYL]-2-YL]METHYL] -N,3,3-TRIMETHYLBUTANAMIDE AND N-(4,5-DIMETHYL-3-ISOXAZOLYL) -2'- (3,3-DIMETHYL-2-OXO-1-PYRROLIDINYL) METHYL] -4'-(2-OXAZOLYL) 1,1'-BIPHE

The compounds N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfon

Studies toward gymnodimine: development of a single-pot Hua reaction for the synthesis of highly hindered cyclic imines.

[structure: see text]. In studies directed toward gymnodimine and related marine toxins, a single-pot variation of the Hua cyclic imine synthesis has been developed. The reaction involves generation of N-trimethylsilyl lactams in situ followed by alkyllithium addition leading directly to cyclic imines. Importantly, this reaction proceeds efficiently with highly hindered alpha,alpha-dialkyl lactams, provided 1,2-dimethoxyethane (DME) is used as solvent, leading to stable cyclic imines. Overall, this transformation allows a one-pot coupling of an alkyliodide and a lactam to give a cyclic imine.